Five ( < 1 % ) patients died after randomisation because of septicaemia ( n = 1 in the dulaglutide 15 mg group ) ; pneumonia ( n = 1 in the dulaglutide 075 mg group ) ; cardiogenic shock ; ventricular fibrillation ; and an unknown cause ( n = 3 in the glargine group ) .